|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: AGO1 |
Gene summary for AGO1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | AGO1 | Gene ID | 26523 |
| Gene name | argonaute RISC component 1 | |
| Gene Alias | EIF2C | |
| Cytomap | 1p34.3 | |
| Gene Type | protein-coding | GO ID | GO:0000956 | UniProtAcc | B2RAD8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 26523 | AGO1 | HCC1_Meng | Human | Liver | HCC | 1.80e-51 | 1.25e-01 | 0.0246 |
| 26523 | AGO1 | HCC2_Meng | Human | Liver | HCC | 1.91e-11 | 7.94e-02 | 0.0107 |
| 26523 | AGO1 | HCC1 | Human | Liver | HCC | 3.78e-04 | 3.77e+00 | 0.5336 |
| 26523 | AGO1 | HCC2 | Human | Liver | HCC | 7.86e-14 | 2.92e+00 | 0.5341 |
| 26523 | AGO1 | S014 | Human | Liver | HCC | 4.83e-17 | 6.33e-01 | 0.2254 |
| 26523 | AGO1 | S015 | Human | Liver | HCC | 6.24e-21 | 7.94e-01 | 0.2375 |
| 26523 | AGO1 | S016 | Human | Liver | HCC | 1.20e-22 | 6.84e-01 | 0.2243 |
| 26523 | AGO1 | S027 | Human | Liver | HCC | 5.73e-07 | 5.43e-01 | 0.2446 |
| 26523 | AGO1 | S028 | Human | Liver | HCC | 6.68e-12 | 4.77e-01 | 0.2503 |
| 26523 | AGO1 | S029 | Human | Liver | HCC | 8.44e-11 | 5.72e-01 | 0.2581 |
| 26523 | AGO1 | male-WTA | Human | Thyroid | PTC | 8.34e-11 | 1.25e-01 | 0.1037 |
| 26523 | AGO1 | PTC01 | Human | Thyroid | PTC | 7.47e-03 | 8.52e-02 | 0.1899 |
| 26523 | AGO1 | PTC04 | Human | Thyroid | PTC | 1.45e-08 | 9.92e-02 | 0.1927 |
| 26523 | AGO1 | PTC05 | Human | Thyroid | PTC | 9.85e-04 | 3.05e-01 | 0.2065 |
| 26523 | AGO1 | PTC06 | Human | Thyroid | PTC | 1.62e-13 | 3.44e-01 | 0.2057 |
| 26523 | AGO1 | PTC07 | Human | Thyroid | PTC | 6.55e-10 | 1.95e-01 | 0.2044 |
| 26523 | AGO1 | ATC12 | Human | Thyroid | ATC | 1.09e-02 | 1.17e-01 | 0.34 |
| 26523 | AGO1 | ATC13 | Human | Thyroid | ATC | 1.16e-38 | 6.69e-01 | 0.34 |
| 26523 | AGO1 | ATC2 | Human | Thyroid | ATC | 4.21e-05 | 4.23e-01 | 0.34 |
| 26523 | AGO1 | ATC4 | Human | Thyroid | ATC | 2.28e-04 | 1.68e-01 | 0.34 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:002261322 | Liver | HCC | ribonucleoprotein complex biogenesis | 355/7958 | 463/18723 | 7.76e-52 | 4.92e-48 | 355 |
| GO:00344702 | Liver | HCC | ncRNA processing | 293/7958 | 395/18723 | 4.26e-38 | 6.76e-35 | 293 |
| GO:00346601 | Liver | HCC | ncRNA metabolic process | 332/7958 | 485/18723 | 1.48e-31 | 7.80e-29 | 332 |
| GO:004427021 | Liver | HCC | cellular nitrogen compound catabolic process | 303/7958 | 451/18723 | 9.76e-27 | 3.64e-24 | 303 |
| GO:004670021 | Liver | HCC | heterocycle catabolic process | 299/7958 | 445/18723 | 2.07e-26 | 7.29e-24 | 299 |
| GO:190136121 | Liver | HCC | organic cyclic compound catabolic process | 325/7958 | 495/18723 | 6.52e-26 | 2.18e-23 | 325 |
| GO:001943921 | Liver | HCC | aromatic compound catabolic process | 309/7958 | 467/18723 | 1.56e-25 | 4.94e-23 | 309 |
| GO:000640121 | Liver | HCC | RNA catabolic process | 201/7958 | 278/18723 | 3.88e-24 | 1.02e-21 | 201 |
| GO:003465521 | Liver | HCC | nucleobase-containing compound catabolic process | 273/7958 | 407/18723 | 4.84e-24 | 1.23e-21 | 273 |
| GO:000640221 | Liver | HCC | mRNA catabolic process | 169/7958 | 232/18723 | 4.50e-21 | 6.96e-19 | 169 |
| GO:007182622 | Liver | HCC | ribonucleoprotein complex subunit organization | 159/7958 | 227/18723 | 3.14e-17 | 3.06e-15 | 159 |
| GO:000641722 | Liver | HCC | regulation of translation | 287/7958 | 468/18723 | 8.79e-17 | 8.08e-15 | 287 |
| GO:002261822 | Liver | HCC | ribonucleoprotein complex assembly | 153/7958 | 220/18723 | 3.44e-16 | 2.91e-14 | 153 |
| GO:000095621 | Liver | HCC | nuclear-transcribed mRNA catabolic process | 84/7958 | 112/18723 | 2.54e-12 | 1.18e-10 | 84 |
| GO:003105021 | Liver | HCC | dsRNA processing | 38/7958 | 54/18723 | 3.15e-05 | 3.21e-04 | 38 |
| GO:007091821 | Liver | HCC | production of small RNA involved in gene silencing by RNA | 38/7958 | 54/18723 | 3.15e-05 | 3.21e-04 | 38 |
| GO:003519621 | Liver | HCC | production of miRNAs involved in gene silencing by miRNA | 36/7958 | 52/18723 | 8.79e-05 | 7.66e-04 | 36 |
| GO:00310541 | Liver | HCC | pre-miRNA processing | 13/7958 | 14/18723 | 1.25e-04 | 1.03e-03 | 13 |
| GO:003424921 | Liver | HCC | negative regulation of cellular amide metabolic process | 144/7958 | 273/18723 | 3.80e-04 | 2.61e-03 | 144 |
| GO:001714821 | Liver | HCC | negative regulation of translation | 129/7958 | 245/18723 | 8.14e-04 | 4.87e-03 | 129 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| AGO1 | SNV | Missense_Mutation | c.1925N>G | p.Tyr642Cys | p.Y642C | Q9UL18 | protein_coding | deleterious(0.03) | possibly_damaging(0.726) | TCGA-A2-A0T2-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | xeloda | PD | |
| AGO1 | SNV | Missense_Mutation | c.1756C>G | p.Gln586Glu | p.Q586E | Q9UL18 | protein_coding | tolerated(0.16) | benign(0.038) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| AGO1 | SNV | Missense_Mutation | novel | c.1444C>T | p.Pro482Ser | p.P482S | Q9UL18 | protein_coding | tolerated(0.07) | benign(0.219) | TCGA-AN-A0FN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| AGO1 | SNV | Missense_Mutation | novel | c.1483N>T | p.Gly495Trp | p.G495W | Q9UL18 | protein_coding | deleterious(0.01) | probably_damaging(0.995) | TCGA-BH-A0AY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | SD | |
| AGO1 | SNV | Missense_Mutation | novel | c.1489N>C | p.Asp497His | p.D497H | Q9UL18 | protein_coding | deleterious(0.01) | possibly_damaging(0.889) | TCGA-BH-A2L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
| AGO1 | SNV | Missense_Mutation | rs745615692 | c.263N>A | p.Arg88His | p.R88H | Q9UL18 | protein_coding | tolerated(0.06) | benign(0.157) | TCGA-C8-A26Z-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | CR |
| AGO1 | SNV | Missense_Mutation | c.1196N>C | p.Val399Ala | p.V399A | Q9UL18 | protein_coding | deleterious(0.01) | possibly_damaging(0.766) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
| AGO1 | SNV | Missense_Mutation | c.851G>A | p.Arg284His | p.R284H | Q9UL18 | protein_coding | tolerated(0.09) | benign(0.02) | TCGA-E2-A15T-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| AGO1 | insertion | Nonsense_Mutation | novel | c.1986_1987insCATTTATCAGCGTTGTAATTTTCACGATTTTTAAAATTAGTCCCT | p.Ile662_Ile663insHisLeuSerAlaLeuTerPheSerArgPheLeuLysLeuValPro | p.I662_I663insHLSAL*FSRFLKLVP | Q9UL18 | protein_coding | TCGA-A2-A04V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | PD | ||
| AGO1 | insertion | Frame_Shift_Ins | novel | c.2145_2146insATGATTATTTACTTCTA | p.Ala716MetfsTer6 | p.A716Mfs*6 | Q9UL18 | protein_coding | TCGA-B6-A0IK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |